Trump directs faster federal reviews of ibogaine research
PUBLISHED Apr 17, 2026, 1:38 AM ET
Read, Watch or Listen
Washington — On Saturday, President Donald Trump signed an executive order directing the administration to accelerate federal reviews of certain psychedelic drugs, notably ibogaine, and to enable federally funded clinical research into their medical uses. The move follows growing veteran interest and private clinics abroad providing ibogaine treatments to Americans who currently travel for access. This action is intended to speed access to trials and research this year while maintaining ibogaine's Schedule I classification for now, according to federal reports. Immediate consequences include potential federal funding paths, statements of support from veterans and conservative lawmakers, and increased scrutiny of safety risks and regulatory oversight in coming months.
By Ayesha A. | JQJO News
Timeline of Events
- Longstanding Schedule I designation restricts federal ibogaine research.
- Veteran groups and private clinics expand cross-border ibogaine use.
- Debate grows over potential therapeutic benefits versus safety risks.
- President signs executive order to accelerate federal psychedelic reviews.
- Agencies prepare protocols, funding routes, and safety oversight for trials.
News Intelligence
- This order could fast-track research into ibogaine, a psychedelic drug, potentially unlocking new treatments for conditions like PTSD. If you or a loved one are seeking alternatives, keep an eye on clinical trials. But remember, ibogaine is still a Schedule I drug with safety risks.
- Articles Published:
- 5
- Right Leaning:
- 1
- Left Leaning:
- 0
- Neutral:
- 4
- Distribution:
- Left 0%, Center 80%, Right 20%
Researchers, clinical trial sites, and some veterans seeking alternative PTSD treatments may gain expanded access to federally supported research pathways and possible trial enrollment.
Patients experimenting outside controlled settings and clinics offering unregulated ibogaine treatments risk harm due to known safety concerns and limited federal oversight during accelerated review processes.
Coverage of Story:
From Left
No left-leaning sources found for this story.
From Center
Trump directs faster federal reviews of ibogaine research
CBS 8 - San Diego News The Star PBS.org Northwest Arkansas Democrat GazetteFrom Right
Trump's Bold Move: Fast-Tracking Psychedelics Like Ibogaine for Revolutionary Mental Health Solutions - Internewscast Journal
Internewscast Journal
Comments